Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus

Figure 4 Virological response in patients with sofosbuvir and ribavirin (SOF/RBV) combination therapy categorized by patient characteristics. A: Age (< 70 or ≥ 70 yr); B: Sex (male or female); C: History of interferon-based therapy (− or +); D: Liver cirrhosis (− or +); E: Fibrosis-4 index (≤ 3.25 or > 3.25); F: History of hepatocellular carcinoma (− or +). ^aP < 0.05: Significant difference. M: Male; F: Female; IFN: Interferon; LC: Liver cirrhosis; FIB: Fibrosis; HCC: Hepatocellular carcinoma.